biostudies-literatureUnknown27(10)Puing AGProphylactic trimethoprim/sulfamethoxazole (TMP/SMX) prevents Pneumocystis jirovecii pneumonia and nocardiosis in immunocompromised patients but sometimes is avoided because of purported allergies or side effects. Of 25 immunocompromised patients receiving alternative prophylaxis in whom nocardiosis developed, 16 subsequently tolerated TMP/SMX treatment. Clinicians should consider TMP/SMX allergy evaluation and rechallenging to assess patient tolerance.Emerging infectious diseases2734-2736https://www.ebi.ac.uk/biostudies/studies/S-EPMC8462344biostudies-literatureNocardiosis in Immunocompromised Patients on Alternative Pneumocystis Prophylaxis.PMC8462344Epstein DJBanaei NPuing AGLiu AYSubramanian AKfalseNocardiosis in Immunocompromised Patients on Alternative Pneumocystis Prophylaxis.Prophylactic trimethoprim/sulfamethoxazole (TMP/SMX) prevents Pneumocystis jirovecii pneumonia and nocardiosis in immunocompromised patients but sometimes is avoided because of purported allergies or side effects. Of 25 immunocompromised patients receiving alternative prophylaxis in whom nocardiosis developed, 16 subsequently tolerated TMP/SMX treatment. Clinicians should consider TMP/SMX allergy evaluation and rechallenging to assess patient tolerance.2021-01-01T00:00:00Z2021 Oct2024-02-15T00:20:35.922Z2022-02-11T16:15:31.11ZS-EPMC84623443454580210.3201/eid2710.210620